The immune-modulator AS101 reduces anti-HLA antibodies in sera of sensitized patients: A structural approach

Moshe Israeli*, Benjamin Sredni, Eitan Mor, Chana Zakai, Boaz Tadmor, Tirza Klein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Background: Significant efforts are dedicated to identification of agents that eliminate anti-HLA antibodies (Ab) from sera of transplant candidates. Antibody titer following in vitro incubation of sera with desensitizing agents has shown to reflect the probability that a patient would benefit from clinical de-sensitization protocols. AS101 is a non-toxic, synthetic, organic tellurium compound. The aim of this research was to assess the ability of AS101 to reduce anti-HLA Abs and to identify patients likely to benefit from this effect. Methods: Sera of sensitized patients awaiting transplant were incubated in the presence of AS101. Measured mean fluorescence intensity (MFI) represents reactivity of anti HLA Abs in the serum, as detected by the Luminex platform. The repertoire of HLA antigen epitopes was recognized using HLA Matchmaker software. Results: AS101 Incubation caused a significant Ab titer decrease in approximately two thirds of the samples. The median Class I and II MFI decrease among the responding samples was 16.7% and 14%, respectively (p < 0.05). HLA Matchmaker analysis of the patients' class I epitope sequences revealed apparent amino-acid differences between the patterns of the responding and non-responding patients. Conclusion: In vitro incubation of sera in the presence of AS101 causes a decrease in the anti-HLA Ab's reactivity in several patient samples. Sera most likely to demonstrate this effect are characterized by a moderate MFI level and a distinct antibody reactivity pattern specific for defined HLA antigen epitopes. These results support further investigation of AS101 as a potential agent for desensitization of humoral reactivity prior to transplantation.

Original languageEnglish
Pages (from-to)483-489
Number of pages7
JournalInternational Immunopharmacology
Issue number4
StatePublished - Aug 2012


FundersFunder number
Safdié Institute for AIDS and Immunology Research
Rothschild Caesarea Foundation


    • AS101
    • Anti-HLA antibodies
    • Epitope
    • HLA Matchmaker
    • Immune-modulator
    • Transplantation


    Dive into the research topics of 'The immune-modulator AS101 reduces anti-HLA antibodies in sera of sensitized patients: A structural approach'. Together they form a unique fingerprint.

    Cite this